Publication | Closed Access

The combination of valacyclovir with an anti-TNF alpha antibody increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis

VaccinationAnti-tnf Alpha AntibodyMurine ModelImmunologyAntiviral Drug DevelopmentSurvival RateVirologyHerpesvirusesAntiviral TherapyAntiviral ResponseAntiviral DrugImmunotherapyMedicineHerpes Simplex Virus Vaccines